Maci 3CM x 5CM implant sheets
Ended Awarded Last action
- Contract number
- SPE2DR26FKAR7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $63,176
Award facts
- Contract value 100% obligated
- $63,175.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded a delivery order valued at $63,175.92 on December 31, 2025, for MACI 3cm x 5cm implant sheets. The award represents a firm fixed-price delivery order under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, with an ultimate completion date of January 23, 2026. MACI (matrix-applied characterization of implants) is a specialized surgical implant product used in orthopedic and regenerative medicine applications. The contract carries no set-aside designation, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. The Defense Logistics Agency, functioning as the funding federal agency, utilized this delivery order mechanism to procure the medical consumable for Department of Defense healthcare operations.
This delivery order is issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency, which was awarded on November 13, 2025, with a ceiling value of $499,999,999 and a completion date of December 31, 2036. The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to ensure reliable pharmaceutical supply chains for military healthcare facilities worldwide. As one of multiple regional prime vendor contractors under this program, DMS Pharmaceutical Group has demonstrated consistent performance across numerous delivery orders spanning oncology treatments, biologics, vaccines, specialty pharmaceuticals, and medical consumables. No subcontractors have been identified in the award documentation, indicating direct fulfillment by the prime contractor.
Quick answers
Who was awarded contract SPE2DR26FKAR7?
SPE2DR26FKAR7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 31, 2025.
How much is contract SPE2DR26FKAR7 worth?
The government has obligated $63,176 on SPE2DR26FKAR7.
Is contract SPE2DR26FKAR7 an order under another contract?
Yes. SPE2DR26FKAR7 is a delivery order under SPE2DR25D9365, an indefinite delivery contract.
Was contract SPE2DR26FKAR7 competed?
The extent of competition for SPE2DR26FKAR7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award